<SEC-DOCUMENT>0001104659-16-119034.txt : 20160509
<SEC-HEADER>0001104659-16-119034.hdr.sgml : 20160509
<ACCEPTANCE-DATETIME>20160509095910
ACCESSION NUMBER:		0001104659-16-119034
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20160509
FILED AS OF DATE:		20160509
DATE AS OF CHANGE:		20160509

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			uniQure N.V.
		CENTRAL INDEX KEY:			0001590560
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36294
		FILM NUMBER:		161630171

	BUSINESS ADDRESS:	
		STREET 1:		MEIBERGDREFF 61
		CITY:			AMSTERDAM
		STATE:			P7
		ZIP:			1005 BA
		BUSINESS PHONE:		31-20-5667394

	MAIL ADDRESS:	
		STREET 1:		MEIBERGDREFF 61
		CITY:			AMSTERDAM
		STATE:			P7
		ZIP:			1005 BA

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	uniQure B.V.
		DATE OF NAME CHANGE:	20131030
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>a16-10821_16k.htm
<DESCRIPTION>6-K
<TEXT>


<html>
<head>



  </head>
<body link=blue lang="EN-US">
<div style="font-family:Times New Roman;">
<div style="border-bottom:solid windowtext 1.0pt;border-left:none;border-right:none;border-top:solid windowtext 3.0pt;padding:1.0pt 0in 1.0pt 0in;">
<p style="border:none;margin:0in 0in .0001pt;padding:0in;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">UNITED STATES</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Washington, D.C. 20549</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">FORM&nbsp;6-K</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="3" face="Times New Roman" style="font-size:12.0pt;font-weight:bold;">Report of Foreign Private Issuer</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="3" face="Times New Roman" style="font-size:12.0pt;font-weight:bold;">Pursuant to Rule&nbsp;13a-16 or 15d-16 of</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="3" face="Times New Roman" style="font-size:12.0pt;font-weight:bold;">the Securities Exchange Act of 1934</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">May&nbsp;9, 2016</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">uniQure N.V.</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Matthew Kapusta, Chief Financial Officer<br> Meibergdreef 61<br> Amsterdam 1105 BA, the Netherlands; Tel: +31-20-240-6000</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Address,&nbsp;Including ZIP Code, and Telephone Number,<br> Including Area Code, of Registrant&#146;s Principal Executive Offices)</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Indicate by check mark whether the registrant files or will file annual reports under cover of Form&nbsp;20-F or Form&nbsp;40-F.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Form&nbsp;20-F </font><font face="Wingdings">x</font>&nbsp;&nbsp;&nbsp;Form&nbsp;40-F&nbsp;<font face="Wingdings">o</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Indicate by check mark if the registrant is submitting the Form&nbsp;6-K in paper as permitted by Regulation S-T Rule&nbsp;101(b)(1):&nbsp;</font><font face="Wingdings">o</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Indicate by check mark if the registrant is submitting the Form&nbsp;6-K in paper as permitted by Regulation S-T Rule&nbsp;101(b)(7):&nbsp;</font><font face="Wingdings">o</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="border-bottom:solid windowtext 3.0pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:1.0pt 0in 1.0pt 0in;">
<p style="border:none;margin:0in 0in .0001pt;padding:0in;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\C902046\16-10821-1\task7942904\10821-1-ba.htm',USER='C902046',CD='May  7 11:29 2016' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Furnished as Exhibit&nbsp;99.1 to this Report on Form&nbsp;6-K is a press release of uniQure N.V. (the &#147;<b>Company</b>&#148;), dated May&nbsp;9, 2016, announcing data from several abstracts presented at the meeting of the American Society of Gene&nbsp;&amp; Cell Therapy.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">2<a name="PB_2_111619_7979"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='2',FILE='C:\JMS\C902046\16-10821-1\task7942904\10821-1-ba.htm',USER='C902046',CD='May  7 11:29 2016' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">SIGNATURES</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.84%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.16%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">UNIQURE   N.V.</font></b></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.84%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.16%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.84%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.16%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Date: May&nbsp;9, 2016</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="45%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/S/ MATTHEW KAPUSTA</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Matthew Kapusta</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Chief Financial Officer</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">3<a name="PB_3_111712_7056"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='3',FILE='C:\JMS\C902046\16-10821-1\task7942904\10821-1-ba.htm',USER='C902046',CD='May  7 11:29 2016' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">INDEX TO EXHIBITS</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="8%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:8.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Number</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="90%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:90.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Description</font></b></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.06%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="90%" valign="top" style="padding:0in 0in 0in 0in;width:90.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.06%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">99.1</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="90%" valign="top" style="padding:0in 0in 0in 0in;width:90.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Press release of uniQure N.V., dated May&nbsp;9,   2016, announcing data from several abstracts presented at the meeting of the   American Society of Gene&nbsp;&amp; Cell Therapy.</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">4<a name="PB_4_111739_5335"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='4',FILE='C:\JMS\C902046\16-10821-1\task7942904\10821-1-ba.htm',USER='C902046',CD='May  7 11:29 2016' -->

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a16-10821_1ex99d1.htm
<DESCRIPTION>EX-99.1
<TEXT>


<html>
<head>




  </head>
<body link=blue lang="EN-US">
<div style="font-family:Times New Roman;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit 99.1</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman"><img width="256" height="57" src="g108211mmi001.jpg"></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">uniQure Presents Preclinical Data on AAV Re-Administration, Regulated Gene Expression and Total Brain Transduction at ASGCT</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Amsterdam, the Netherlands, May&nbsp;9, 2016 &#151; </font></b>uniQure N.V. (NASDAQ: QURE), a leader in human gene therapy, today announced the data from several preclinical research programs focused on the development and validation of new technologies to improve gene therapy as a therapeutic approach. The results were presented in poster sessions at the American Society of Gene and Cell Therapy (ASGCT) 19<font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">th</font>&#160;Annual Meeting in Washington D.C., and highlight the progress uniQure has made in establishing optimized gene therapy delivery systems, re-administration protocols and vector technologies specifically in its key focus areas, liver/metabolism and CNS.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;The data presented at the ASGCT demonstrate the significant progress we have made in both our research programs and for our technology platform,&#148; said Dr.&nbsp;Harald Petry, Chief Scientific Officer of uniQure. &#147;uniQure has made several important advances in the design and optimization of gene therapy technology that we believe will significantly expand the application and overall effectiveness of our modular platform. We&#146;ve applied these novel technologies &#151; including optimized gene therapy delivery systems, re-administration protocols, regulated gene expression and improved vector design &#151; across a number of preclinical programs targeting liver and CNS diseases, and remain committed to making gene therapy available to more patients across the globe.&#148;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Each of the scientific posters from the ASGCT conference are available on the uniQure website.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Summary of ASGCT presentations:</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">Liver/Metabolic Disease</font></u></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Changing the Route of Administration to Improve Liver Transduction by Recombinant AAV-Based Vectors:</b> This study, conducted in non-human primates (NHPs) with uniQure&#146;s partners at the Centro de Investigaci&#243;n M&#233;dica Aplicada (CIMA) in Pamplona, Spain, highlights the potential of alternative administration routes to improve delivery into the liver to achieve higher transduction efficiency and expression levels. High expression levels are crucial for the treatment of diseases associated with a deficiency of enzymatic activity in the liver such as Hemophilia A and B The results demonstrated that direct administration via the hepatic artery with balloon occlusion of the suprahepatic vein can achieve higher transgene expression and transduction efficiency compared to standard administration techniques.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><i style="font-weight:bold;">Successful Repeated Hepatic Gene Delivery by Sequential Administration of AAV5 and AAV1 Vector Serotypes:</i></b> This study<i>, </i>using different AAV serotypes (AAV5 and AAV1) for repeated liver-targeted gene delivery in NHP&#146;s,&#160; demonstrated that combining different AAV serotypes in a potential therapeutic regimen is a successful strategy for re-administration.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><i style="font-weight:bold;">Development of MFP-Inducible System for AAV5 Gene Therapy of Chronic Diseases in the Liver:</i></b> The study conducted in cell culture and mice provides a proof of concept for repeated regulation of transgene expression and a novel vector system for future gene therapy development in disease states where modification of the therapeutic level of gene expression would be advantageous.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">CNS Disease</font></u></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><i style="font-weight:bold;">Directional Transduction of AAV5 Vectors in the NHP Brain:</i></b> The goal of this study was to evaluate the transduction efficiency and vector distribution pattern following MRI-guided delivery to improve delivery of a gene therapy into specific regions of the brain.&#160; The results indicate a dose dependent distribution profile which could be modified to mediate expression patterns as a potential therapeutic strategy to treat a broad range of neurodegenerative diseases.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\C902046\16-10821-1\task7942904\10821-1-mm.htm',USER='C902046',CD='May  7 11:21 2016' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">Gene Therapy Technology</font></u></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><i style="font-weight:bold;">Successful In Vivo Re-Administration of AAV with the Use of Two-Step AAV injection:</i></b> uniQure researchers evaluated the feasibility of a re-administration protocol utilizing a two-step AAV injection approach to decrease levels of circulating neutralizing antibodies (NAbs) in mice. Results demonstrated a significant dose-dependent reduction in anti-AAV5 antibodies following AVV &#145;decoy&#146; injection.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><i style="font-weight:bold;">Analysis of AAV5 Biodistribution and Viral Shedding in the Presence or Absence of Neutralizing Antibodies</i></b><b>: </b>This study investigated the effect of the presence of neutralizing antibodies&#160; on gene therapy efficiency administered to mice. Results indicated that for patients with already existing NAbs, or for the purpose of re-administration, alternative administration routes are needed to strengthen gene therapy application. The study showed significant decreases in the biodistribution of AAV5 in the presence of NAbs. Furthermore, the presence of NAbs increased following infection without a cellular immune response against the vector.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">About uniQure</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">uniQure is delivering on the promise of gene therapy &#151; single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with CNS, liver/metabolic and cardiovascular diseases. www.uniQure.com</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">uniQure Forward-Looking Statement</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as &#147;anticipate,&#148; &#147;believe,&#148; &#147;could,&#148; &#147;estimate,&#148; &#147;expect,&#148; &#147;goal,&#148; &#147;intend,&#148; &#147;look forward to&#148;, &#147;may,&#148; &#147;plan,&#148; &#147;potential,&#148; &#147;predict,&#148; &#147;project,&#148; &#147;should,&#148; &#147;will,&#148; &#147;would&#148; and similar expressions. Forward-looking statements are based on management&#146;s beliefs and assumptions and on information available to management only as of the date of this press release. These forward-looking statements include, but are not limited to, statements regarding the development of our gene therapies the success of our collaborations and the risk of cessation, delay or lack of success of any of our ongoing or planned clinical studies and/or development of our product candidates. Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, risks associated with collaboration arrangements, our and our collaborators&#146; clinical development activities, regulatory oversight, product commercialization and intellectual property claims, as well as the risks, uncertainties and other factors described under the heading &#147;Risk Factors&#148; in uniQure&#146;s 2014 Annual Report on Form&nbsp;20-F filed with the Securities and Exchange Commission on April&nbsp;7, 2015 and its 2015 Annual Report on Form&nbsp;20-F filed with the Securities and Exchange Commission on April&nbsp;4, 2016. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future.</font></i></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">uniQure:</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Eva Mulder</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Direct: +31 20 240 6103</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Main: +31 20 240 6000</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">e.mulder@uniQure.com</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Media inquiries:</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Gretchen Schweitzer or Stephanie May</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">MacDougall Biomedical Communications</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Direct: +49 172 861 8540 or +49 175 5711562</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Main: +49 89 2424 3494 or +1 781 235 3060</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">gschweitzer@macbiocom.com</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\C902046\16-10821-1\task7942904\10821-1-mm.htm',USER='C902046',CD='May  7 11:21 2016' -->

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g108211mmi001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g108211mmi001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1"  Y 0 # 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#V:BDS1F@!
M:**3- "T4F:* %HI,T9H 6BDS2T 9NNZF=*TQYU ,A(2,'ID_P#U@:XR'Q1J
MD<XD>X\Q<\HRC!_3BNYU33X]3L9+:3C=RK?W6[&N5M_!-U]H7[1/#Y(/S%"2
MQ'MQ7D8^GBI58NE>WE^I[& J86-*2K)7\^WD=C;3K=6T<\>=DBAAGT(S3Y'6
M)&=R%51DD] *2*-(8ECC4*B *H'8"N3\9ZI(KI81,0A7=+COZ#]*[L17^KTN
M>6_ZG!AZ'UBKR1V_0?J?C18Y#'IT:R ?\M'SC\!69_PF&I[LYAQZ;*S-.T^;
M4[M;>W W'DD]%'J:Z4>!E\GF]/F^NSY?YUXD*F.Q5YP>GW'N3IX'"VA-*_GJ
M&F^- \H348E13_RTC!P/J*ZJ*5)HUDC8,C#*L#P17F.I:;/I=T8+@#.,JR]&
M'J*W_!NJ2"=K"1B8RI:,'^$]Q73@L=453V-??]3FQN ING[>AM^AV5%)VHS7
MMGABT4E+0 44E+0 44F:,T +129HH 6BDS1F@!:*** ,CQ2[1Z!<,C%6!7D'
M!^\*X>RNIS?6X,\I!D7C>?6NV\5_\B]<?5/_ $(5P=C_ ,?]M_UU7^=?/9I)
MK$QMV7YL^BRN*>&E==7^2/5:XWQK-+%?VXCD= 8_X6([UV5<5XX_Y"%M_P!<
MC_.O1S1M89V\CSLK2>)5_,E\%322W-T))'?"+C<Q/<UN^(V9-!NF5BK!1@@X
M/45S_@;_ (^;O_<7^9K?\2_\B_=_[H_]"%985OZ@WY2_4UQ:7U]+SC^AY_'?
M7$<B/YTIVD'!<\U+>ZO>7\A>>X<@GA <*/PJFHW,%'4G%>EV&BV=C:B%(4?^
M\SJ"6->5@\/5Q*E%2LD>KC,12PW+*4;M['G=O?W5HX:WN)8R/1CC\J] T'6!
MK%F790DL9VNHZ?45R?BK3(=.U!#;KLCF7=M'0'/./:KG@9B+RZ7L8P3^!_\
MKUT8*=3#XKV$GH<^-A2Q&%]O%:G2ZXQ71+ME)!$9P0:\\M[JX-Q$#/+C>/XS
MZUZ%KW_("O/^N1KSBV_X^8O]\?SJ\VDU6C;M^I&4).C._?\ 0]6%>=^*7+>(
MKGVV@?\ ?(KT2O./$G_(P7?^\/\ T$5TYP_W*]?T9RY,OW[]/U1N>!HE\J[D
MP-Q95S[<UUE<QX'_ ./"Y_ZZ_P!*Z>NG+E;#0_KJ<V8N^)G_ %T.7\<1 V5K
M)CE9"N?J/_K5S_AM]GB"T/JQ'Y@BND\;_P#(*@_Z[C_T$US'A_\ Y#MG_P!=
M*\G&:8Z+7='KX+7 23[,]*[5Y5]KN/\ GO+_ -]FO5:\EK?.6UR6\_T.?)4G
MSW\OU/3M');1[-F)),*9)[\5F>,Y'BTB(QNR'SP,J<?PM6GHW_(%LO\ K@G\
MA63XW_Y T/\ U\#_ -!:N[$/_8WZ'%AU_MB]3G_#MS,^O6JO-(RECD%B1]TU
MZ%7G'AK_ )&"T_WC_P"@FO1ZY\G;=&5^_P"B-\X25:-NWZL\K:[N-[?OY>O]
M\U9N=<OKF**(SND4:! J,1NP,9/KFJ+??;ZUW?AO1;6#38IWC62:=0Y9P#@'
MH!7DX2E5Q$W",K+J>OBZM+#P4Y1N^AQ$,]PDJF"642$\;&.2:[F759]$T6)]
M299;MLA57O\ 4^W<U?31[**_^V1P(LVW P.![X]?>N/\8W!EUKRL_+"@&/<\
M_P!17?[*>7TI3<KMZ+MZG![6&858PY;):OOZ>AG7FL7M](6GN),'HBG"C\*K
MQW,\#;HYI(V]58BNE\'VEIY4MW<M%Y@?8@<CY1P<C/U_2N@U*"PU*T>&:6 D
MCY6W#*GU%84\#4K4_:N>K_K<WJXZG0J>Q5/1?UL8GAWQ1)+-'9WYWLYPDOOZ
M'_&NMKR4%D8$'#*>#Z&O4-,NC>Z;;W# !I$!8#IGO7;E>*E53IS=VCAS7"QI
M-5(*R?YE#Q7_ ,B]<?5/_0A7!V/_ !_V_P#UU7^=>@>)86GT"Z51DA0WY$$_
MH*\Y5BC*RG!4Y!KDS;3$1EY?JSLRC7#RCY_HCUNN*\<'_B86W_7+^M:5KXRL
MGME-R)$F ^957()]JY76=4?5[]IV&U -J+Z+_C71F.+HU*'+!W;.;+L)6IU^
M:<;)&UX&_P"/F[_W%_F:W_$O_(OW?^Z/_0A6!X&_X^;O_<7^9K?\2_\ (OW?
M^Z/_ $(5IA/]P?I+]2,7_P C!>L?T/.H?]='_O"O6:\FA_UT?^\*]9K')=I_
M+]37.MX?/]#C?'/_ !\VG^XW\Q3/ _\ Q_W/_7+^M/\ '/\ Q\VG^XW\Q3/
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<>_TKJ0,# Z4M%=M##TZ$>6FCAKXBI7ES5&?_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
